|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Current** | Rota 2019  PMID: [31046087](http://pubmed.gov/31046087) | Snowsill (NHS), 2018 PMID [26013989](http://pubmed.gov/26013989) | Wang 2018  PMID [2997938](http://pubmed.gov/2997938) | Usman Ali 2016  PMID: [27130532](http://pubmed.gov/27130532) | Coureau 2016 PMID: [27211572](http://pubmed.gov/27211572) | Fu 2014  PMID [25307063](http://pubmed.gov/25307063) | Humphrey (USPSTF) 2013  PMID: [23897166](http://pubmed.gov/23897166) | Manser (Cochrane) 2013 PMID [23794187](http://pubmed.gov/23794187) |
| Number of studies | 9 | 7 | 4 | 4 | 4 | 5 | 4 | 4 | 1 |
| Efficacy for lung cancer mortality reduction | 0.86 (0.75, 0.93) | 0.80 (0.71, 0.90) | 0.94 (0.74, 1.19)  Exclude MILD  0.85 (0.74, 0.98) | 1.13 (0.78, 1.64)  Exclude MILD  1.02 (0.66, 1.58) | Did not pool all trials | NA | 0.84 (0.74, 0.96) Studies mislabeled | Meta-analysis not performed due to heterogeneity | 0.80 (0.70, 0.92) |
| Heterogeneity | 25% | 19% | 43%  6.9% | 87%  Exclude MILD 85% | NA | NA | 48% | High | NA (1 study) |
| Efficacy for overall mortality reduction | 0.95 (0.91, 1.00) |  | 1.00 (0.87, 1.16)  Exclude MILD  0.95 (0.89, 1.00) | NA | Did not pool all trials | NA | 1.04 (0.72, 1.51)  Studies mislabeled | Meta-analysis not performed due to heterogeneity | 0.94 (0.88, 1.00) |
| Heterogeneity | 0% | 19% | **43%** | 87% | NA | NA | 48% | High | **NA** |